## MITHRA PHARMACEUTICALS S.A.

ISIN: BE0974283153 WKN: A14V4E Asset Class: Stock



## **Company Profile**

Mithra Pharmaceuticals SA is a biotechnology company, which engages in the business of transforming women's health by offering new choices through innovation with a particular focus on contraception and menopause. It operates through the following segments: Product Sales, Out-Licensing, and Other. The Product Sales segment includes complex therapeutics, estetrol, and the remaining portfolio of generic products. The Out-Licensing segment offers partnership deals. The Other segment is involved in the research and development services rendered to third parties. The company was founded by Jean-Michel Foidart and Fran?ois Fornieri on July 8, 1999 and is headquartered in Liege, Belgium.

## Financial figures, Fiscal year: from 01.01. to 31.12.

	2023 2022		2021			
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	93,408,000		145,863,000		99,389,000	
Common stock capital		50,594,000		41,228,000		32,250,000
Fixed assets	193,138,000		296,551,000		322,529,000	
Equity capital of a company		-103,255,000		33,687,000		33,840,000
Cash and cash equivalents	8,980,000		28,285,000		32,872,000	
Accrued liabilities		266,000		266,000		266,000
Other assets	-		-		-	
Current liabilities		103,981,000		130,431,000		95,793,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		285,822,000		278,296,000		292,285,000
Different income		-		-		-
Other liabilities		105,314,000		97,595,000		118,339,000
Total assets	286,546,000	286,546,000	442,414,000	442,414,000	421,918,000	421,918,000

Balance notes			
	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS

Accounting standard	IFRS	IFRS	IFRS
Employees	-	229	248
Equity ratio	-36.03%	7.61%	8.02%
Debt-equity ratio	-377.51%	1,213.31%	1,146.80%

Others			
	2023	2022	2021
Tax Expense Rate	-7.24%	-339.64%	7.49%

## MITHRA PHARMACEUTICALS S.A.

ISIN: BE0974283153 WKN: A14V4E Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	40,155,000	66,997,000	22,668,000
Net income	-173,502,000	-59,620,000	-116,875,000
EBIT	-140,641,000	3,470,000	-114,222,000
Operating income before taxes	-161,795,000	-13,561,000	-126,337,000
Cash Flow	-2,184,000	-66,681,000	-86,152,000
Net interest income	-21,154,000	-17,031,000	-12,115,000
Research and development expenses	63,170,000	64,041,000	85,243,000
Income taxes	11,707,000	46,059,000	-9,462,000
Result from investments in subsidaries, associates and other	-	0	0
Revenues per employee	-	292,563	91,403

<b>Board of Directors</b>	
Obsisting Haman	Obsigned of Oversa in the Decard
Christian Homsy	Chairman of Supervisory Board
Jean-Michel Foidart	Member of Supervisory Board
Inge Beernaert	Member of Supervisory Board
Jacques Galloy	Member of Supervisory Board
Valérie Gordenne	Member of Supervisory Board

Members of Management Board			
David Horn Solomon	Chairman of Managing Board		
Benjamin Brands	Member of Executive Committee		
Christophe Maréchal	Member of Executive Committee		
Graham Dixon	Member of Executive Committee		
Jean-Manuel Fontaine	Member of Executive Committee		
Jean-Michel Foidart	Member of Executive Committee		